Clinical trials: Cytomegalovirus Disease
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
This phase II trial studies how well Triplex vaccine works in preventing cytomegalovirus (CMV) infection in patients undergoing a hematopoietic stem cell transplantation.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT04060277
- Testing
- Letermovir, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Glioblastoma Multiforme, GBM
Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
Patients have a type of brain cancer called glioblastoma multiforme. Because most GBMs come back after standard therapy, patients are being asked to volunteer to take part in a research study using special immune cells.
- Conditions
- Glioblastoma Multiforme, GBM, Brain Cancer
- Trial name
- COGLI (NCT01205334)
- Testing
- Autologous CMV-specific CTL
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Baylor College of Medicine
Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm
Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection
This phase II trial studies how well donor cytomegalovirus-specific cytotoxic T-lymphocytes work in treating patients with a cytomegalovirus infection that has come back or has not gotten better despite standard therapy.
- Conditions
- Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT02210078
- Testing
- Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma, Malignant Glioma
Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
The purpose of this study is to determine the feasibility and safety of administering CMV RNA-pulsed dendritic cells (DCs), also known as CMV-DCs, to children and young adults up to 35 years old with nWHO Grade IV glioma…
- Conditions
- Glioblastoma, Malignant Glioma, Medulloblastoma Recurrent, Pediatric Glioblastoma Multiforme
- Trial name
- ATTAC-P (NCT03615404)
- Testing
- CMV-DCs with GM-CSF, Td (tetanus toxoid)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Gary Archer Ph.D.
Cytomegalovirus Infections, Acute Leukemia
Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
Letermovir is approved for the primary prevention of Cytomegalovirus (CMV) reactivation and infection in hematopoietic stem cell transplant recipients.
- Conditions
- Cytomegalovirus Infections, Acute Leukemia, B Cell Lymphoma
- Trial name
- CMV CAR-T (NCT06058858)
- Where
- 3 sites in France
- Volunteers
- 250 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cytomegalovirus Disease, Cytomegalovirus Infections
Letermovir Use in Heart Transplant Recipients
This is an open label trial in which letermovir will be given as prophylaxis for the prevention of cytomegalovirus (CMV) infection and disease to all heart transplants who are at risk for cytomegalovirus.
- Conditions
- Cytomegalovirus Disease, Cytomegalovirus Infections, Heart Transplant Infection, Antiviral Toxicity
- Trial name
- NCT04904614
- Testing
- Letermovir
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Tufts Medical Center
Viral Infection, Viral Reactivation
Third Party Viral Specific T-cells (VSTs)
The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.
- Conditions
- Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host
- Trial name
- NCT02532452
- Testing
- Viral Specific VST Infusion
- Where
- 4 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Chronic Myeloproliferative Disorders, Leukemia
Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
RATIONALE: Tests that measure certain changes in blood in patients at high risk of cytomegalovirus infection may help doctors learn more about predicting cytomegalovirus infection after donor stem cell transplant.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00716911
- Testing
- ganciclovir, polymerase chain reaction, flow cytometry
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Cytomegalovirus (CMV)
A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
This study is about treatment options for cytomegalovirus infections in people who have received stem cell transplants. The main aim of the study is to check if the cytomegalovirus infection can no longer be detected after…
- Trial name
- NCT02927067
- Testing
- Maribavir, Valganciclovir
- Where
- 129 sites in United States, Australia and 21 more
- Volunteers
- 553 people
- Sponsor
- Shire
Cytomegalovirus Retinitis, HIV Infections
A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)
To assess the relative efficacy of oral versus intravenous hydration during foscarnet sodium (Foscavir) induction therapy, as determined by changes in creatinine clearance.
- Trial name
- NCT00002125
- Testing
- Foscarnet sodium
- Where
- 11 sites in United States
- Volunteers
- 112 people
- Sponsor
- Astra USA
Heart Transplantation, Cardiac Allograft Vasculopathy
Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy
Cardiac allograft vasculopathy (CAV) is the major cause of long-term graft failure in heart transplant recipients. Although several immune-mediated and metabolic risk factors have been implicated in the pathogenesis of CAV, no…
- Conditions
- Heart Transplantation, Cardiac Allograft Vasculopathy, Cytomegalovirus Infection
- Trial name
- PROTECT (NCT00966836)
- Testing
- Pre-emptive strategy with valganciclovir plus everolimus, Prophylaxis with valganciclovir plus mycophenolate, Prophylaxis with valganciclovir plus everolimus
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Bologna
Cytomegalovirus Infections
Recombinant CMV gB Vaccine in Postpartum Women
The purpose of this study is to determine if a new cytomegalovirus (CMV) vaccine (CMV gB/MF59) can safely prevent mothers from catching CMV infection between pregnancies.
- Trial name
- NCT00125502
- Testing
- CMV gB vaccine, MF59 adjuvant
- Where
- 2 sites in United States
- Volunteers
- 464 people, healthy volunteers welcome
- Sponsor
- Robert Pass, MD
Heart Transplant Infection, Kidney Transplant Infection
CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
CMV infection and disease remain a significant clinical challenge for pediatric solid organ transplant (SOT) recipients. Current prevention strategies are limited to prophylaxis in which antiviral medication is administered for a…
- Conditions
- Heart Transplant Infection, Kidney Transplant Infection, Liver Transplant Infection, CMV
- Trial name
- NCT03924219
- Testing
- CMV T cell Immunity Assay
- Where
- 12 sites in United States
- Volunteers
- 161 people
- Sponsor
- Vanderbilt University Medical Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV)…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Trial name
- NCT06059391
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor
- Where
- 3 sites in United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Cytomegalovirus Infections
Treatment of Low Dose IL-2 and Ganciclovir in Cytomegalovirus Infection
Cytomegalovirus (CMV) infections is a severe infection in patients of rheumatic disease treated with corticosteroid and immunosuppressive agents.
- Trial name
- NCT04225780
- Testing
- Low-dose IL-2 and ganciclovir
- Volunteers
- 10 people
- Sponsor
- Peking University People's Hospital
Cytomegalovirus (CMV) Infection, Kidney Transplantation
A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients
HB-101 is a bivalent recombinant vaccine against human CMV infection. This is a randomized, placebo-controlled, phase 2 study to assess the safety, reactogenicity, immunogenicity, and efficacy of HB-101 in CMV-Seronegative…
- Trial name
- NCT03629080
- Testing
- HB-101 vaccine
- Where
- 25 sites in United States, Denmark and 4 more
- Volunteers
- 83 people
- Sponsor
- Hookipa Biotech GmbH
Disorder of Cardiac Function
Myocardial Screening in Fetuses With Congenital Cytomegalovirus (CMV) Infection
BACKGROUND Myocarditis and pericarditis are inflammatory conditions of the heart commonly due to viral or autoimmune etiologies. Human CMV represents one of the leading causes of congenital infections worldwide.
- Trial name
- NCT02787382
- Testing
- echocardiographic examination
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Adenovirus Infection, BK Virus Infection
Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
This is a Phase 2 study to evaluate posoleucel (ALVR105, formerly Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- Prevent (NCT04693637)
- Testing
- Posoleucel (ALVR105)
- Where
- 16 sites in United States
- Volunteers
- 26 people
- Sponsor
- AlloVir
Cytomegalovirus
Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see how well transfusions of T-cells work in treating CMV. T-cells are a type of white blood cell that helps protect the body from infection.
- Trial name
- NCT01646645
- Testing
- CMV-pp65 CTLs
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus [CMV] specific cytotoxic T-lymphocytes [CTLs]) or allogeneic adenovirus-specific cytotoxic T…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus, Donor, Solid Organ Transplantation Recipient
- Trial name
- NCT03665675
- Testing
- Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes, Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sumithira Vasu